Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: bispecific antibody therapy - MAT Biopharma

Drug Profile

Research programme: bispecific antibody therapy - MAT Biopharma

Alternative Names: Anti-CD5/anti-CD32 bispecific antibody therapy - MAT Biopharma; Bispecific antibody cancer therapy - MAT Biopharma

Latest Information Update: 23 Feb 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MAT Biopharma
  • Class Bispecific antibodies
  • Mechanism of Action Apoptosis stimulants; CD5 antigen inhibitors; IgG receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 23 Feb 2011 Discontinued - Preclinical for Chronic lymphocytic leukaemia in France (Parenteral)
  • 13 Jun 2005 Preclinical trials in Chronic lymphocytic leukaemia in France (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top